Halozyme Therapeutics (HALO) P/S ratio

P/S ratio today
8.5×

Halozyme Therapeutics (HALO) trades at 8.5× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 6.0×. That is 2.0% lower than the 6.1× of fiscal 2024. Figures as of 18 Nov 2026, 10:46 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
8.5×
P/S ratio, fiscal 2025
6.0×
Change on fiscal 2024
−2.0%
Highest on record
22.6×fiscal 2020
Lowest on record
6.0×fiscal 2025
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Halozyme Therapeutics P/S ratio, in more detail

Today's figure is 42.6% above the fiscal 2025 year-end.

Across the 11 fiscal year-ends on record (2015–2025), the highest was 22.6× in fiscal 2020 and the lowest 6.0× in fiscal 2025. Today's P/S ratio is higher than at 27% of the 11 fiscal year-ends on record; their median is 12.1×.

History · 11 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Halozyme Therapeutics P/S ratio, year by year

Halozyme Therapeutics (HALO) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today8.5×—$95.97—
20256.0× 2.0% down$67.30$11.27
20246.1× 1.9% up$47.81$7.84
20236.0× 50.7% down$36.96$6.18
202212.1× 9.0% down$56.90$4.69
202113.3× 41.0% down$40.21$3.02
202022.6× 72.9% up$42.71$1.89
201913.1× 5.6% down$17.73$1.36
201813.8× 55.5% up$14.63$1.06
20178.9× 3.3% up$20.26$2.28
20168.6× 47.0% down$9.88$1.15
201516.3×—$17.33$1.07
2014——$9.65—
2013——$14.99—
2012——$6.71—
2011——$9.51—
2010——$7.92—
2009——$5.87—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Halozyme Therapeutics and comparable companies
CompanyP/S ratio
Kymera Therapeutics KYMR264.6×
DaVita DVA0.8×
Halozyme Therapeutics HALO7.8×
Universal Health Services UHS0.6×
Repligen RGEN14.0×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics P/S ratio: questions and answers

What is Halozyme Therapeutics's P/S ratio?

Halozyme Therapeutics (HALO) trades at 8.5× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 6.0×. That is 2.0% lower than the 6.1× of fiscal 2024.

Is Halozyme Therapeutics's P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 27% of the 11 fiscal year-ends on record; their median is 12.1×.

What are the highest and lowest P/S ratio figures on record for Halozyme Therapeutics?

Across the 11 fiscal year-ends on record (2015–2025), the highest was 22.6× in fiscal 2020 and the lowest 6.0× in fiscal 2025.

How is Halozyme Therapeutics's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Halozyme Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.